微海绵药物输送系统:促进抗炎药物的治疗效率
Akshay Kumar1, Rakesh1, Rajesh Gautam1
1School of Pharmaceutical Sciences, CT University, Sidhwan khurd, Ferozpur road, Ludhiana, Punjab, India-142024.
Anti-inflammatory & anti-allergy agents in medicinal chemistry
|December 8, 2025
概括
微海绵药物递送系统提供抗炎药物的可控释放,改善生物可用性和减少慢性炎症疾病的副作用. 这种创新方法通过较少的剂量和有针对性的输送,提高了患者的遵从性.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 药物输送系统 药物输送系统
背景情况:
- 慢性炎症疾病需要长期使用抗炎药物治疗.
- 像NSAIDs和皮质类固醇这样的传统疗法具有局限性,包括全身毒性和频繁的给药.
- 微海绵药物递送系统为增强抗炎药物疗效提供了一种新的解决方案.
研究的目的:
- 探索微海绵药物输送系统对于抗炎药物的潜力.
- 研究微海绵如何提高药物的生物可用性,稳定性和向性输送.
- 评估微海绵在治疗关节炎,IBD和牛皮等慢性炎症疾病中的应用.
主要方法:
- 制造有孔的聚合物微球 (5-300微米),封装活性药物成分 (API).
- 使用了先进的技术,如乳液溶剂扩散,液体-液体悬浮聚合和电动力学原子化.
- 评估药物负载,释放动力学,稳定性和特定炎症条件的体内性能.
主要成果:
- 微海绵实现了持续的药物释放,最大限度地减少了全身副作用和剂量频率.
- 证明药物稳定性增强和在目标部位保持度增加.
- 在关节炎 (扩展活性),IBD (结肠特异性分娩) 和牛皮 (增强透) 中展示了特定的益处.
结论:
- 微海绵技术显著改善了抗炎药物的治疗结果.
- 这些系统通过减少剂量频率和不良影响来提高患者的遵守性.
- 微海绵药物输送是慢性炎症疾病中药物和临床应用的转型平台.
相关概念视频
Drug Delivery: Miscellaneous Routes
694
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
694
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.5K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.5K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
184
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
184
Bioavailability Enhancement: Drug Permeability Enhancement
176
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
176
Bioavailability Enhancement: Drug Solubility Enhancement
199
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
199
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431


